Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.36 |
| ▸ | CA2 | P00918 | 6/20 | 0.36 |
| ▸ | CA9 | Q16790 | 6/20 | 0.36 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25487999 | 0.87 | CA1 (0.41) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL25481221 | 0.87 | LMNA (0.41) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL21702711 | 0.85 | LMNA (0.39) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL21415409 | 0.82 | POLB (0.39) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL20813605 | 0.81 | LMNA (0.41) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL14500640 | 0.79 | THRB (0.43) | LMNACA1CA2CA9CA12 | |
| SCHEMBL31319784 | 0.77 | LMNA (0.37) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL25481224 | 0.77 | CYP3A4 (0.36) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL23812505 | 0.76 | CYP3A4 (0.36) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL17640848 | 0.76 | LMNA (0.36) | LMNAKMT2APOLBALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3757215-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3137091-B1 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2015168532-A2 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168618-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168635-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2014179626-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179625-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179629-A2 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179620-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |